- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Jugular venous pressure.
Displaying page 1 of 2.
EudraCT Number: 2012-001642-17 | Sponsor Protocol Number: AMB116457 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004972-20 | Sponsor Protocol Number: PST2744-DM-04-012 | Start Date*: 2007-01-18 | |||||||||||
Sponsor Name:Sigma-Tau i.f.r. S.p.A. | |||||||||||||
Full Title: A Phase II Study to assess the hemodynamic effects of ISTAROXIME, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function. | |||||||||||||
Medical condition: Chronic heart failure and left ventricular systolic dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003059-36 | Sponsor Protocol Number: Bay 58-2667/12480 | Start Date*: 2007-12-10 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with acute deco... | |||||||||||||
Medical condition: Patients with acute decompensated chronic congested heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003153-28 | Sponsor Protocol Number: ALN-TTRSC02-003 | Start Date*: 2019-12-23 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: HELIOS-B: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Outcomes, Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with C... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) PT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SI (Completed) NO (Trial now transitioned) IE (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) HR (Trial now transitioned) CZ (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002403-13 | Sponsor Protocol Number: Ularitide-1502 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:PDL BioPharma Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure | |||||||||||||
Medical condition: Acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001604-17 | Sponsor Protocol Number: APHP220428 | Start Date*: 2022-11-15 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris | |||||||||||||
Full Title: Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers | |||||||||||||
Medical condition: Patients With Acute Heart Failure and Elevated Inflammatory Markers in Emergency Department | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014378-16 | Sponsor Protocol Number: Bay 58-2667/14663 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002893-35 | Sponsor Protocol Number: CP027.2002 | Start Date*: 2013-11-21 |
Sponsor Name:Trevena Inc. | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure | ||
Medical condition: Heart Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002774-39 | Sponsor Protocol Number: PDY15079 | Start Date*: 2018-01-23 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | |||||||||||||
Full Title: An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients with Worsening Heart ... | |||||||||||||
Medical condition: Cardiac Failure aggravated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007395-42 | Sponsor Protocol Number: 160HF301 | Start Date*: 2008-09-25 | |||||||||||
Sponsor Name:Biogen Idec Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insuffic... | |||||||||||||
Medical condition: Acute Decompensated Heart Failure and Renal Insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FI (Completed) IT (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005426-18 | Sponsor Protocol Number: DECONGEST_v1.0 | Start Date*: 2022-03-02 | |||||||||||
Sponsor Name:UZ Brussel | |||||||||||||
Full Title: Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001646-18 | Sponsor Protocol Number: AMB115811 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005213-11 | Sponsor Protocol Number: NES103694 | Start Date*: 2005-03-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with a... | |||||||||||||
Medical condition: Acute decompensated heart failure (adHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) IE (Completed) SK (Completed) HU (Prematurely Ended) IS (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) DK (Completed) LV (Completed) EE (Completed) FI (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017082-39 | Sponsor Protocol Number: Bay 58-2667 / 14836 | Start Date*: 2010-02-01 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003835-20 | Sponsor Protocol Number: ALN-TTRSC-004 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl... | |||||||||||||
Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021572-29 | Sponsor Protocol Number: AMB114588 | Start Date*: 2010-11-23 | |||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development, Ltd | |||||||||||||||||||||||||||||||||
Full Title: An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued... | |||||||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GR (Prematurely Ended) DE (Completed) NL (Ongoing) ES (Completed) HU (Completed) IT (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001467-36 | Sponsor Protocol Number: FER-CARS-06 | Start Date*: 2017-02-02 | |||||||||||||||||||||
Sponsor Name:Vifor (International) Inc. | |||||||||||||||||||||||
Full Title: A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart F... | |||||||||||||||||||||||
Medical condition: Acute heart failure with iron deficiency | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) NL (Completed) PL (Completed) HR (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004280-32 | Sponsor Protocol Number: AG10-301 | Start Date*: 2019-05-10 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003692-35 | Sponsor Protocol Number: ZKSJ0109 | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:Friedrich Schiller University Jena | |||||||||||||
Full Title: Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
